NVS — Novartis AG

Novartis Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales Growth: Novartis reported an 8% increase in sales for the full year 2025, achieving $61.8 billion.
• Core Operating Income: Up 14% to $21.9 billion, with a core margin of 40.1%, reached two years ahead of schedule.
• Q4 Performance: Sales declined 1% in Q4 due to gross-to-net adjustments and the loss of exclusivity (LOE) for Entresto. Core operating income increased by 1%.
• Core EPS: Rose 17% to $8.98 for the year; Q4 core EPS was $2.03, up 2%.
• Free Cash Flow: Reached an all-time high of $17.6 billion, up 8% year-over-year.

2. Strategic Updates and Business Highlights

• Pipeline Advancements: Significant pipeline progress with submissions for remibrutinib and pelabresib, and ongoing studies in various therapeutic areas.
• Key Growth Drivers:
  • Kisqali: Sales increased 57% to $4.8 billion; remains a strong growth driver with a peak sales outlook of $10 billion.
  • Kesimpta: Grew 36% to $4.4 billion, with strong adoption in MS.
  • Pluvicto: Achieved $2 billion in sales, with strong growth in the U.S. and upcoming launches in Japan and China.
  • Scemblix: Blockbuster status achieved, with 87% growth in Q4.
  • Leqvio: Reached blockbuster status, with 57% growth for the year.
• New Product Launches: Rhapsido and Itvisma showing promising early results, with potential for significant market impact.

3. Forward Guidance and Outlook

• 2026 Guidance: Sales expected to grow low single digits, with core operating income projected to decline low single digits due to anticipated dilution from the Avidity deal.
• Long-term Growth: Confident in a 5% to 6% sales CAGR from 2025 to 2030, with a return to 40% core margin expected by 2029.
• Pipeline Readouts: Seven pivotal readouts anticipated in 2026, which could strengthen midterm growth prospects.

4. Bad News, Challenges, or Points of Concern

• Generic Competition: Significant impact from U.S. generics on Entresto, Promacta, and Tasigna, affecting Q4 performance and expected to continue into 2026.
• Sales Decline in Q4: The decline in sales attributed to one-time gross-to-net adjustments and LOE for key products.
• Market Dynamics: Concerns about competition in the MS market and the potential impact of oral SERDs on Kisqali's market share.
• Event Rate in Trials: Lower-than-expected event rates in the pelacarsen trial could impact the perceived value of the treatment.

5. Notable Q&A Insights

• Remibrutinib: Confidence in the safety profile, with discussions ongoing with the FDA regarding liver monitoring requirements.
• Pelacarsen: Potential for a lower-than-expected treatment effect but still a viable product if the study shows significant benefits.
• Kisqali's Future: Plans to extend the Kisqali franchise through ongoing clinical programs and potential acquisitions in oncology.
• Rhapsido Launch: Early positive results but access remains a key factor for growth.
• Food Allergy Opportunity: Excitement around remibrutinib's potential in food allergies, with plans for a Phase III program based on upcoming data.

This summary encapsulates Novartis's performance and strategic direction as discussed in the Q4 2025 earnings call, highlighting both achievements and challenges ahead.